Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.71
ARDM's Cash-to-Debt is ranked lower than
53% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. ARDM: 1.71 )
Ranked among companies with meaningful Cash-to-Debt only.
ARDM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84  Med: 5.07 Max: No Debt
Current: 1.71
Equity-to-Asset 0.04
ARDM's Equity-to-Asset is ranked lower than
90% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ARDM: 0.04 )
Ranked among companies with meaningful Equity-to-Asset only.
ARDM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.48 Max: 0.91
Current: 0.04
-0.16
0.91
Piotroski F-Score: 1
Altman Z-Score: -27.03
Beneish M-Score: 94.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -15395.90
ARDM's Operating Margin % is ranked lower than
99% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. ARDM: -15395.90 )
Ranked among companies with meaningful Operating Margin % only.
ARDM' s Operating Margin % Range Over the Past 10 Years
Min: -15395.9  Med: -470.36 Max: -11.49
Current: -15395.9
-15395.9
-11.49
Net Margin % -16891.28
ARDM's Net Margin % is ranked lower than
99% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. ARDM: -16891.28 )
Ranked among companies with meaningful Net Margin % only.
ARDM' s Net Margin % Range Over the Past 10 Years
Min: -16891.28  Med: -549.46 Max: 13.86
Current: -16891.28
-16891.28
13.86
ROE % -260.15
ARDM's ROE % is ranked lower than
95% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ARDM: -260.15 )
Ranked among companies with meaningful ROE % only.
ARDM' s ROE % Range Over the Past 10 Years
Min: -352.08  Med: -183.67 Max: 12.78
Current: -260.15
-352.08
12.78
ROA % -105.68
ARDM's ROA % is ranked lower than
94% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. ARDM: -105.68 )
Ranked among companies with meaningful ROA % only.
ARDM' s ROA % Range Over the Past 10 Years
Min: -108.56  Med: -68.01 Max: 8.91
Current: -105.68
-108.56
8.91
ROC (Joel Greenblatt) % -10736.99
ARDM's ROC (Joel Greenblatt) % is ranked lower than
97% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. ARDM: -10736.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARDM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11062.32  Med: -683.16 Max: 1095.34
Current: -10736.99
-11062.32
1095.34
3-Year Revenue Growth Rate -77.00
ARDM's 3-Year Revenue Growth Rate is ranked higher than
98% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. ARDM: -77.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARDM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.4  Med: -12.5 Max: 136.2
Current: -77
-81.4
136.2
3-Year EBITDA Growth Rate -1.10
ARDM's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. ARDM: -1.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARDM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.1  Med: -26.4 Max: 10.6
Current: -1.1
-61.1
10.6
3-Year EPS without NRI Growth Rate -1.90
ARDM's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ARDM: -1.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARDM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.3  Med: -30.4 Max: 20
Current: -1.9
-56.3
20
GuruFocus has detected 4 Warning Signs with Aradigm Corp $ARDM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARDM's 10-Y Financials

Financials (Next Earnings Date: 2017-05-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ARDM Guru Trades in Q1 2016

John Paulson 19,662 sh (New)
Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q2 2016

ARDM Guru Trades in Q2 2016

John Paulson 65,903 sh (+235.18%)
Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q3 2016

ARDM Guru Trades in Q3 2016

John Paulson 146,918 sh (+122.93%)
Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q4 2016

ARDM Guru Trades in Q4 2016

Jim Simons 27,900 sh (New)
John Paulson 192,727 sh (+31.18%)
First Eagle Investment 3,854,730 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 334510    SIC: 3845
Compare:OTCPK:NTFU, NAS:MYOS, OTCPK:CBICF, NAS:APRI, OTCPK:PARNF, NAS:BNTC, OTCPK:PTLF, OTCPK:GLDFF, OTCPK:PVCT, OTCPK:CVSI, OTCPK:KAYS, OTCPK:AOLS, OTCPK:BKIT, OTCPK:CYIG, AMEX:IGC, OTCPK:LBLTF, OTCPK:AQSZF, OTCPK:RLMD, NAS:FCSC, OTCPK:TLFMF » details
Headquarter Location:USA
Aradigm Corp is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases.

Aradigm Corp, a California corporation was incorporated on January 30, 1991 . It is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company's development candidates include proprietary formulations of the potent antibiotic ciprofloxacin or Pulmaquin ARD-3150 and Lipoquin ARD-3100 that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. Its proprietary programs under development include, Inhaled Ciprofloxacin and Smoking Cessation Therapy. Ciprofloxacin has been approved by the FDA as an anti-infective agent and is widely used for the acute treatment of a variety of bacterial infections, including exacerbations associated with pulmonary infections. ARD-1600 Inhaled Nicotine is used for Smoking Cessation Therapy. It competes with pharmaceutical and biotechnology companies, hospitals, research organizations, individual scientists and nonprofit organizations engaged in the development of drugs and other therapies for the respiratory disease indications. It had 74 issued United States patents, with 14 additional United States patent applications pending. The research, development, testing, manufacturing, labeling, advertising, promotion, distribution, marketing and export, among other things, of any products it develops are subject to extensive regulation by governmental authorities in the United States and other countries.

Top Ranked Articles about Aradigm Corp

First Eagle Adds to Stake in Aradigm Guru buys more than half a million shares in pharmaceutical company
First Eagle Investment (Trades, Portfolio) raised its stake in Aradigm Corp. (NASDAQ:ARDM), a Hayward, California-based pharmaceutical company, by nearly 15% with the purchase of 575,815 shares on April 25. Read more...

Ratios

vs
industry
vs
history
PB Ratio 19.25
ARDM's PB Ratio is ranked higher than
54% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. ARDM: 19.25 )
Ranked among companies with meaningful PB Ratio only.
ARDM' s PB Ratio Range Over the Past 10 Years
Min: 0.76  Med: 3.24 Max: 232.43
Current: 19.25
0.76
232.43
PS Ratio 105.84
ARDM's PS Ratio is ranked lower than
98% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ARDM: 105.84 )
Ranked among companies with meaningful PS Ratio only.
ARDM' s PS Ratio Range Over the Past 10 Years
Min: 1.21  Med: 12.73 Max: 1146.67
Current: 105.84
1.21
1146.67
EV-to-EBIT -0.40
ARDM's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. ARDM: -0.40 )
Ranked among companies with meaningful EV-to-EBIT only.
ARDM' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.8  Med: -1.7 Max: 19.3
Current: -0.4
-17.8
19.3
EV-to-EBITDA -0.40
ARDM's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. ARDM: -0.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARDM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.5  Med: -1.8 Max: 18.3
Current: -0.4
-18.5
18.3
Current Ratio 4.24
ARDM's Current Ratio is ranked higher than
78% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. ARDM: 4.24 )
Ranked among companies with meaningful Current Ratio only.
ARDM' s Current Ratio Range Over the Past 10 Years
Min: 1.29  Med: 4.24 Max: 10.5
Current: 4.24
1.29
10.5
Quick Ratio 4.24
ARDM's Quick Ratio is ranked higher than
80% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ARDM: 4.24 )
Ranked among companies with meaningful Quick Ratio only.
ARDM' s Quick Ratio Range Over the Past 10 Years
Min: 1.29  Med: 4.24 Max: 10.5
Current: 4.24
1.29
10.5
Days Sales Outstanding 312.59
ARDM's Days Sales Outstanding is ranked lower than
81% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ARDM: 312.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.34  Med: 14.93 Max: 571.49
Current: 312.59
2.34
571.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.60
ARDM's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ARDM: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARDM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.3  Med: -35.3 Max: -0.6
Current: -0.6
-63.3
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 25.40
ARDM's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. ARDM: 25.40 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARDM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.58  Med: 6.12 Max: 32
Current: 25.4
2.58
32
Price-to-Tangible-Book 18.14
ARDM's Price-to-Tangible-Book is ranked higher than
62% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. ARDM: 18.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARDM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.25  Med: 3.51 Max: 30.22
Current: 18.14
1.25
30.22
Price-to-Median-PS-Value 8.47
ARDM's Price-to-Median-PS-Value is ranked lower than
99% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ARDM: 8.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARDM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.51 Max: 10.67
Current: 8.47
0.13
10.67
Earnings Yield (Greenblatt) % -243.72
ARDM's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. ARDM: -243.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARDM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -258.51  Med: 437.2 Max: 73513.7
Current: -243.72
-258.51
73513.7

More Statistics

Revenue (TTM) (Mil) $0.20
EPS (TTM) $ -2.23
Beta1.54
Short Percentage of Float0.92%
52-Week Range $1.23 - 7.19
Shares Outstanding (Mil)14.95
» More Articles for ARDM

Headlines

Articles On GuruFocus.com
First Eagle Adds to Stake in Aradigm Apr 28 2016 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
Aradigm reports 4Q loss Mar 28 2017
Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results Mar 28 2017
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017... Feb 09 2017
Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9 Jan 06 2017
Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Dec 02 2016
Don’t Write Off Aradigm Corporation (ARDM) Just Yet Dec 02 2016
Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin Dec 01 2016
Aradigm posts mixed late-stage data on inhaled antibiotic Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16 Nov 10 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin Oct 18 2016
Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting... Oct 07 2016
Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in... Sep 22 2016
Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City Sep 21 2016
Aradigm (ARDM) Shares March Higher, Can It Continue? Sep 21 2016
Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27 Sep 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)